Likewise, eptinezumab treatment led to a notable reduction in MAI in CM (−28 ± 44.9, p = 0.014), whereas the reduction observed in HFEM (−0.7 ± 5.7) did not reach statistical significance.
← all excerpts
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study.
1
—
—